E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 6/22/2006 in the Prospect News Biotech Daily and Prospect News PIPE Daily.

New Issue: ISTA Pharmaceuticals will pocket $40 million from convertibles

By Sheri Kasprzak

New York, June 22 - ISTA Pharmaceuticals, Inc. has entered into agreements to wrap a $40 million private placement of senior subordinated convertible notes.

The 8% notes are due in five years and are convertible into common shares at $7.75 each, a 22.2% premium to the company's $6.34 closing stock price on June 21.

The investors in the offering include HBK Master Fund LP; Deerfield Partners, LP; Deerfield International Ltd.; Sprout Capital IX, LP; Sprout Entrepreneurs Fund, LP; Sprout IX Plan Investors, LP; Visium Balanced Fund, LP; Visium Balanced Offshore Fund, Ltd.; Visium Long Bias Offshore Fund, Ltd.; Atlas Master Fund, Ltd.; LBI Group, Inc.; and Highbridge International LLC.

The deal is set to close on June 23.

Banc of America Securities LLC is the placement agent.

After the third anniversary, the holders may require ISTA to repurchase the notes at par plus interest.

Proceeds from the offering will be used for the commercialization of ISTA's lead product containing prednisolone acetate and tobramycin. The launch of the product is expected to coincide with the company's filing of a New Drug Application with the Food and Drug Administration and the FDA's acceptance and approval of the application.

Located in Irvine, Calif., ISTA is a specialty pharmaceutical company focused on treatments for eye conditions like dry eye, vitreous hemorrhage, diabetic retinopathy, glaucoma and ocular pain.

Issuer:ISTA Pharmaceuticals, Inc.
Issue:Senior subordinated convertible notes
Amount:$40 million
Maturity:Five years
Coupon:8%
Price:Par
Yield:8%
Conversion price:$7.75
Initial conversion premium:22.2%
Warrants:No
Investors:HBK Master Fund LP; Deerfield Partners, LP; Deerfield International Ltd.; Sprout Capital IX, LP; Sprout Entrepreneurs Fund, LP; Sprout IX Plan Investors, LP; Visium Balanced Fund, LP; Visium Balanced Offshore Fund, Ltd.; Visium Long Bias Offshore Fund, Ltd.; Atlas Master Fund, Ltd.; LBI Group, Inc.; and Highbridge International LLC
Placement agent:Banc of America Securities LLC
Announcement date:June 22
Settlement date:June 23
Stock symbol:Nasdaq: ISTA
Stock price:$6.34 at close June 21

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.